Renaissance Technologies
VIRX

Renaissance Technologies’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Renaissance Technologies’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-286,395
Closed -$46.1K – 3968
2024
Q4 		$46.1K Buy
286,395
+40,996
+17% +$8.07K ﹤0.01% 3401
2024
Q3 		$56.8K Buy
245,399
+27,700
+13% +$10.2K ﹤0.01% 3331
2024
Q2 		$118K Buy
217,699
+15,200
+8% +$12K ﹤0.01% 3154
2024
Q1 		$207K Buy
202,499
+23,600
+13% +$17.2K ﹤0.01% 3219
2023
Q4 		$102K Buy
178,899
+30,700
+21% +$18.8K ﹤0.01% 3297
2023
Q3 		$154K Buy
148,199
+13,400
+10% +$18.2K ﹤0.01% 3153
2023
Q2 		$190K Buy
134,799
+9,500
+8% +$13.6K ﹤0.01% 3317
2023
Q1 		$199K Sell
125,299
-14,488
-10% -$26.3K ﹤0.01% 3289
2022
Q4 		$204K Buy
139,787
+43,888
+46% +$128K ﹤0.01% 3412
2022
Q3 		$409K Buy
95,899
+2,500
+3% +$10.6K ﹤0.01% 3046
2022
Q2 		$362K Buy
93,399
+45,399
+95% +$129K ﹤0.01% 3346
2022
Q1 		$228K Sell
48,000
-67,700
-59% -$204K ﹤0.01% 3597
2021
Q4 		$422K Buy
+115,700
New +$617K ﹤0.01% 3162
2019
Q4 		– Sell
-2,387
Closed -$60K – 3795
2019
Q3 		$60K Sell
2,387
-4,971
-68% -$143K ﹤0.01% 3315
2019
Q2 		$187K Buy
7,358
+5,597
+318% +$216K ﹤0.01% 3314
2019
Q1 		$75K Buy
+1,761
New +$39.9K ﹤0.01% 3332
2017
Q4 		– Sell
-2,128
Closed -$144K – 3531
2017
Q3 		$144K Sell
2,128
-463
-18% -$37.8K ﹤0.01% 3056
2017
Q2 		$245K Sell
2,591
-604
-19% -$69.3K ﹤0.01% 2952
2017
Q1 		$458K Buy
3,195
+36
+1% +$5.15K ﹤0.01% 2792
2016
Q4 		$400K Buy
3,159
+457
+17% +$63.6K ﹤0.01% 2837
2016
Q3 		$413K Buy
2,702
+1,405
+108% +$198K ﹤0.01% 2861
2016
Q2 		$149K Buy
1,297
+963
+288% +$107K ﹤0.01% 3105
2016
Q1 		$38K Buy
+334
New +$50.6K ﹤0.01% 3299
2014
Q3 		– Sell
-109
Closed -$149K – 2987
2014
Q2 		$149K Sell
109
-2
-2% -$2.32K ﹤0.01% 2613
2014
Q1 		$153K Buy
+111
New +$129K ﹤0.01% 2658

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Renaissance Technologies's VIRX Position: Q1 2025 in Review

Renaissance Technologies sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 286,395 shares — an estimated $46.1K sold.

Renaissance Technologies first reported a position in VIRX in Q1 2014 and held it in 25 quarters. The position peaked at $458K in Q1 2017. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • Renaissance Technologies reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Renaissance Technologies sold 286,395 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $46.1K.
  • Renaissance Technologies first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 25 quarters.
  • Renaissance Technologies's Viracta Therapeutics, Inc. Common Stock position peaked at $458K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.